Discloses use of Interleukin-7 (IL-7), for the manufacture of a medicament for the treatment of hepatitis C in a patient infected with hepatitis C virus, wherein the patient has been treated with an antiviral agent or a combination of antiviral agents, so as to reduce viral load, before administration with IL-7, wherein the antiviral agent or combination of antiviral agents reduces the viral load to less than 5 Log10 IU/mL.